Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
05/21/2018 05/22/2018 05/23/2018 05/24/2018 05/25/2018 Date
5.1(c) 5.98(c) 6.36(c) 6.71(c) 6.76(c) Last
1 786 126 7 730 396 2 592 344 1 566 034 794 294 Volume
+6.36% +17.25% +6.35% +5.50% +0.75% Change
More quotes
Financials (GBP)
Sales 2018 14,9 M
EBIT 2018 -37,0 M
Net income 2018 -39,3 M
Finance 2018 23,5 M
Yield 2018 -
Sales 2019 24,1 M
EBIT 2019 -33,5 M
Net income 2019 -36,1 M
Debt 2019 19,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0,81x
EV / Sales2019 2,27x
Capitalization 35,6 M
More Financials
Company
Vernalis Plc is a commercial stage pharmaceutical company.Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic and amoxicillin; and frovatriptan, used for the acute treatment of migraine.Vernalis also develops and... 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
03/20VERNALIS : Update on Strategic Review Formal Sale Process and Forthcoming Direct..
AQ
03/15VERNALIS : Update on Strategic Review, Formal Sale Process and Forthcoming Direc..
AQ
03/05VERNALIS : Trading and Corporate Update
AQ
02/28VERNALIS : Trading and Corporate Update
AQ
2017VERNALIS : enters into research collaboration with Daiichi Sankyo
AQ
2017VERNALIS : AGM Statement
PU
2017VERNALIS PLC : AGM Statement
MW
2017VERNALIS : enters into research collaboration with Daiichi Sankyo
PU
2017VERNALIS : + Daiichi Sankyo Enter Collaboration
MW
2017VERNALIS : and Servier Achieve Research Milestone in Third Oncology Collaboratio..
PU
More news
Sector news : Biotechnology & Medical Research - NEC
05/25The Heated Quest for Opioid Alternatives -2-
DJ
05/25The Heated Quest for Opioid Alternatives
DJ
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/25Critical Contrast: Oramed Pharmaceuticals $ORMP versus Vernalis $VNLPY  
03/15Thursday quiz: who can name all the biotech companies that had been merged in.. 
03/15Until May 2018, it seems. Ian Garland and David Mackney to leave $VER.L
1
More tweets
Qtime:35
News from SeekingAlpha
2017Vernalis reports FY results 
2017SNIPPET ROUNDUP : A Small Success For Galapagos And A Big One For Karius 
20173 THINGS IN BIOTECH YOU SHOULD LEARN : April 23, 2017 
2017FDA rejects Vernalis' marketing application cough/cold med CCP-07 
2017Vernalis reports 1H results 
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 0,27  GBP
Spread / Average Target 299%
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Mike Wood Research Director
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-22.57%47
CELLTRION, INC.--.--%32 036
IQVIA HOLDINGS INC2.66%20 818
LONZA GROUP2.20%20 226
INCYTE CORPORATION-29.61%14 505
NEKTAR THERAPEUTICS33.89%13 705